rs324011 — STAT6

Intronic variant in STAT6 (intron 2) that creates an NF-κB binding site, increasing STAT6 promoter activity; the T allele is associated with elevated total serum IgE and increased risk for atopic dermatitis, asthma, and allergic rhinitis through enhanced Th2 signaling

See your personal result for STAT6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

STAT6 — The Th2 Master Switch That Sets Your Allergy Thermostat

STAT6 (Signal Transducer and Activator of Transcription 6)11 STAT6 (Signal Transducer and Activator of Transcription 6)
A transcription factor activated by interleukin-4 (IL-4) and interleukin-13 (IL-13) that drives Th2 immune responses — the arm of the immune system responsible for allergy, asthma, and eczema. When IL-4 or IL-13 binds its receptor, STAT6 becomes phosphorylated, dimerizes, and migrates to the nucleus where it switches on genes for IgE production, eosinophil recruitment, and airway remodeling is the central transcription factor of the Th2 immune axis — the pathway that governs allergic disease. The rs324011 variant, located in intron 2 of the STAT6 gene on chromosome 12, is one of the most studied intronic polymorphisms in atopic disease genetics. Unlike missense variants that alter the protein's structure, this variant acts as a regulatory switch: it controls how much STAT6 gets made in the first place.

The Mechanism

The rs324011 variant lies within the second intron of STAT6, in a region that influences the gene's transcriptional regulation. The T allele creates a functional NF-κB binding site22 NF-κB binding site
NF-κB (Nuclear Factor kappa B) is a master inflammatory transcription factor that, when activated by immune signals, binds to specific DNA sequences and drives expression of inflammatory genes; creating a new binding site in the STAT6 gene means NF-κB can now directly upregulate STAT6 transcription. A luciferase reporter assay33 luciferase reporter assay
A laboratory technique where the gene's regulatory region is fused to a light-emitting reporter gene; more light = more transcription confirmed that the T allele of rs324011 significantly increases STAT6 promoter activity compared to the C allele. The biological consequence is straightforward: cells with the T allele make more STAT6 protein, so the same IL-4 or IL-13 signal generates a stronger Th2 response.

The C allele does not create this NF-κB binding site, leaving STAT6 under tighter transcriptional control. This difference in gene dosage is enough to produce measurable differences in circulating IgE levels — the antibody class that orchestrates allergic reactions through mast cell and basophil activation.

The Evidence

The clearest functional evidence comes from a Taiwanese cohort study. Lee et al. 201544 Lee et al. 2015
Taiwan Children Health Study; STAT6 genetic variants and childhood atopic dermatitis in a Taiwanese population; J Dermatol Sci 2015 found that the T allele was associated with childhood atopic dermatitis with an odds ratio of 1.23 (95% CI 1.01–1.51), and functionally validated the NF-κB mechanism using luciferase reporter assays in cell lines.

At the population level, Weidinger et al. 200455 Weidinger et al. 2004
J Med Genet; 1,407 German adults from the KORA cohort showed that rs324011 is significantly associated with total serum IgE (p=0.015), and that a STAT6 haplotype carrying this variant drove a dose-response relationship across IgE percentiles — OR 1.7 at the 100 kU/L threshold rising to OR 2.54 at the 90th percentile for very high IgE. The dose-response pattern across IgE thresholds supports a genuine causal relationship rather than a statistical artifact.

A meta-analysis of six studies totaling 1,431 asthma cases and 2,027 controls Qian et al. 201466 Qian et al. 2014
Hum Immunol; meta-analysis of STAT6 polymorphisms and asthma risk found that TT homozygotes had a 26–29% higher asthma risk compared to CT+CC (recessive model OR 1.26, 95% CI 1.02–1.55). The 2017 GWAS from Ferreira et al. using 360,838 participants with asthma, hay fever, and eczema confirmed the STAT6 locus among the 136 shared genetic risk variants for atopic disease.

Practical Implications

For T allele carriers, the elevated STAT6 expression creates a lower threshold for Th2 immune activation, meaning atopic reactions (eczema flares, allergic rhinitis, asthma) may be triggered by lower allergen exposures than in CC individuals. Total serum IgE — a direct readout of this pathway — is a clinically available biomarker that can quantify how active the Th2 axis currently is and whether interventions are working.

Quercetin77 Quercetin
A flavonoid found in onions, apples, capers, and supplemented as a powder or capsule; acts as a natural STAT6 and NF-κB inhibitor at concentrations achievable in cell culture; evidence is mechanistic rather than from clinical trials has been shown in vitro to inhibit STAT6 phosphorylation and suppress IL-5 and IL-13 production from CD4+ T cells, directly targeting the pathway this variant upregulates. This is a biologically rational intervention for T allele carriers, though clinical trial data in atopic disease are limited.

Pharmacogenomically, dupilumab (Dupixent) — the monoclonal antibody blocking the shared IL-4/IL-13 receptor subunit (IL-4Rα) — directly counteracts the molecular pathway amplified by this variant. While prescribing decisions for dupilumab are currently based on clinical severity rather than genotype, carriers of the T allele who develop moderate-to-severe atopic dermatitis or asthma are operating in a pathway biologically well-matched to dupilumab's mechanism of action.

Interactions

The rs324011 variant acts in the same Th2 signaling axis as IL13 rs20541 (R130Q), which produces a hyperactive IL-13 protein that drives stronger STAT6 activation downstream. Carriers of risk alleles at both loci face a double amplification: more STAT6 protein (rs324011-T) being activated more potently (rs20541-A/IL-13 Q130 isoform). The IL4 receptor alpha variant rs1801275 (Q576R) is a third member of this axis — it sensitizes the receptor to IL-4/IL-13 signaling, feeding into the same STAT6 pathway. The combined genetic burden across these three variants predicts both disease severity and total IgE levels better than any single variant alone.

Drug Interactions

dupilumab dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Standard STAT6 expression with typical Th2 immune tone

You have two copies of the C allele at rs324011. The C allele does not create the NF-κB binding site found in the T variant, so your STAT6 gene remains under tighter transcriptional control. Cell-based reporter assays show that C allele cells produce less STAT6 protein per unit of inflammatory signal compared to T allele carriers. This is associated with lower baseline total serum IgE and a somewhat higher threshold for Th2 immune activation. About 40% of people of European ancestry carry this genotype; it is the most common genotype in African and East Asian populations (~70% and ~56%, respectively).

CT Intermediate

One copy of the NF-κB binding variant associated with modestly elevated STAT6 expression

The rs324011 T allele creates a functional binding site for NF-κB, the master inflammatory transcription factor. When NF-κB is activated by infections, allergen exposure, or other inflammatory triggers, it can now directly upregulate STAT6 transcription through this newly created binding site — a regulatory mechanism that C allele carriers lack. The net effect is higher STAT6 protein levels, which amplifies the downstream Th2 signaling cascade: more IgE class switching in B cells, more eosinophil recruitment, more IL-4 and IL-13 production. As a heterozygote, only one of your two chromosomes carries this enhanced regulatory element, producing an intermediate phenotype. The rs324011/rs167769 STAT6 intron 2 haplotype was associated with atopic dermatitis (global p=0.0018) in the Taiwan Children Health Study.

TT High Risk

Two copies of the STAT6 NF-κB binding variant with highest Th2 amplification

TT homozygosity at rs324011 means every STAT6 mRNA produced in your cells is initiated from a promoter that can be directly upregulated by NF-κB. Because NF-κB itself is activated by allergen exposures, infections, and inflammatory cytokines, there is a feed-forward loop: allergen exposure triggers NF-κB → NF-κB upregulates STAT6 → more STAT6 amplifies IL-4/IL-13 signaling → more IgE, more eosinophils, more airway inflammation. This self-amplifying circuit explains the dose-response observed in the Weidinger 2004 cohort, where STAT6 haplotype carriers (with rs324011) showed progressively higher ORs as the IgE threshold was raised — reaching OR 2.54 for very high IgE (90th percentile). For TT homozygotes, both alleles are active participants in this amplification.

The meta-analysis by Qian et al. (6 studies, 1,431 asthma cases, 2,027 controls) found TT vs CC OR of 1.29 (95% CI 1.03–1.63) for asthma, consistent with the Yemeni pediatric cohort's OR of 2.5 (95% CI 1.2–5.0) for atopic asthma under a recessive model. The range across studies reflects population differences in linkage disequilibrium patterns and environmental co-triggers.

The STAT6 pathway is directly targeted by the biologic dupilumab (anti-IL-4Rα), which blocks both IL-4 and IL-13 signaling. TT carriers who develop moderate-to-severe atopic disease represent patients whose underlying biology is biologically well-matched to this mechanism of action.